Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) (CYTORELEASE)
Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)
Sponsor: CytoSorbents, Inc
This NA trial investigates CAR-T and Cytokine Release Syndrome and is currently ongoing. CytoSorbents, Inc leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Oct 2024 — Sep 2025 [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
May 2021 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
-
Sep 2019 — Feb 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CytoSorbents, Inc
- Hannover Medical School
For direct contact, visit the study record on ClinicalTrials.gov .